Genentech & Avastin can't seem to catch a break! First the FDA asked Genentech to generate more data on MBC, and now this.
<blockquote>Genentech and FDA notified healthcare professionals about revisions to the WARNINGS and ADVERSE REACTIONS sections of the prescribing information to inform healthcare professionals of 1] cases of a rare brain-capillary leak syndrome [reversible posterior leukoencephalopathy syndrome (RPLS)] and 2] postmarketing reports of nasal septum perforation.</blockquote>
Unfortunately there are not a lot of options available to patients with cancer. So, while this is not a good piece of news for Avastin or Genentech, the impact of this is likely to be minimal.
Avastin is a great drug, but like all great drugs, Avastin too has its negatives. Patients and Doctors need to consider these risk/benefits when prescribing all medicines, and Avastin is no exception.
